Clinical Outcomes and Risk Factors of Hepatitis B Virus Recurrence in Patients Who Received Prophylaxis With Entecavir and Hepatitis B Immunoglobulin Following Liver Transplantation

Kim, Y.-K.; Kim, S.H.; Lee, S.D.; Park, S.-J.

doi:10.1016/j.transproceed.2013.08.065

Cited by 16 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recurrent HCC remained an alarming signal. Its association with HBV reactivation was revealed by Idilman R, Lee WC et al who con rmed 21.4% to 100% cases of recurrence detected with concomitant HCC recurrence 32,39,44,50 . For HP NAs, the recurrent HCC was supposed to present following challenges: HBV within tumor cells might be relatively inaccessible to drug because of the change in liver structure and blood supply.…”

Section: Discussionmentioning

confidence: 91%

The Strategy and Efficacy of Prophylaxis Against Hepatitis B Virus Recurrence After Liver Transplantation in the Era of High Potent Nucleos(t)ide Analogues: A Meta-Analysis

Li¹,

Hou²,

Yao³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: High potent nucleos(t)ide analogues (HP NAs) with or without hepatitis B immunoglobulin (HBIG) is the standard prophylactic therapy for avoiding the HBV recurrence after liver transplantation (LT). While the clinical impact of HP NAs-based prophylaxis has not been well documented, the optimal treatment strategy is currently debated. This meta-analysis aims to evaluate clinical outcome of LT recipients under HP NAs-based regimens and investigate different prophylaxis schemes. Methods: We followed PRISMA statement to conduct this study. Two reviewers independently searched relevant literature via PubMed, EMBAES, MEDLINE, Web of Science, and Google Scholar. Studies were included if they observed HBV recurrence under HP NAs-based regimens in patients who received HBV-related LT. Primary and secondary outcome were HBV recurrence, HCC recurrence, all-cause and HBV-recurrence related mortality. Incidence with 95% confidence intervals was aggregated and assess by fixed effect model/random effect model. Subgroup analysis was applied to examine the impact of different treatment strategies. Results: 26 studies (n=2374) were included, with a pooled HBV recurrence rate of 0.92% (95% CI 0.47%-1.48%). Studies with and without HBV viremia or HDV superinfected patients demonstrated comparable HBV recurrence (p=0.25, p=0.69). Recurrence rate under indefinite combination of HP NAs and HBIG was lower than that under HP NAs monotherapy (p=0.0003), and similar to that under NAs plus finite course of HBIG (p=0.53). Pooled HCC recurrence rate was 5.34% (95% CI 0.78%-12.48%). HBV-recurrence related mortality and all-cause mortality were 0.17% (95% CI 0.00%-1.51%) and 7.29% (95% CI 4.42%–10.71%) respectively. Conclusion: Our study suggests HP NAs-based regimens provide satisfactory HBV antiviral prophylaxis and improved long-term outcome for LT recipients. Finite combination of HP NAs and HBIG is an alternative to lifelong dual therapy.

show abstract

Section: Discussionmentioning

confidence: 91%

The Strategy and Efficacy of Prophylaxis Against Hepatitis B Virus Recurrence After Liver Transplantation in the Era of High Potent Nucleos(t)ide Analogues: A Meta-Analysis

Li¹,

Hou²,

Yao³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In 4 of those 5 patients, recurrence of HCC was detected prior to the recurrence of HBV. Recurrent HCC was found to be an independent risk factor for the recurrence of HBV (P = 0.06) [18]. Na et al reported that 4 of 262 recipients who received entecavir combined with HBIG experienced a recurrence of HBV infection after liver transplantation during the median 49-mo follow-up period.…”

Section: Hbig Plus Entecavirmentioning

confidence: 99%

Hepatitis B immune globulin and HBV-related liver transplantation

Akay¹,

Karasu²

2016

MMJ

View full text Add to dashboard Cite

The risk of recurrence of liver cirrhosis and hepatocellular carcinoma due to hepatitis B virus (HBV) infection was 90% following liver transplantation before 1990's but now we rarely see recurrence due to the highly effective prophylactic treatments. In this review, we discussed the achievements of the prophylactic treatments in patients transplanted for HBV diseases. Options for hyperimmune globulin usage and high genetic barier anti-viral drugs can be used to prevent the recurrence. Keywords: Liver transplant, Hepatitis B hyperimmune globulin, Recurrence ÖZHepatit B nedeni ile oluşan karaciğer sirozu veya hepatosellüler karsinoma hastalarında karaciğer transplantasyonu sonrası nüks 1990'lı yıllarda ciddi bir sorun olarak gündemde bulunmaktaydı. Ancak hiperimmun globulin tedavileri ve yüksek direnç bariyerli ilaçlar ile günümüzde nüks sorunu hemen hemen ortadan kalkmıştır. Bu derlemede bu hastalarda kullanılan profikaltik tedavi seçenekleri tartışılmıştır.Anahtar kelimeler: Karaciğer transplantasyonu, Hepatit B hyperimmun globulin, Nüks

show abstract

“…However, relatively few studies have examined combined prophylaxis with HBIG plus ETV or TDF. Overall, these studies have found recurrence rates ranging from 0% to 4% [20][21][22][23][24][25][26] . Nevertheless, no randomized studies have yet compared the efficacy of combined prophylaxis with HBIG + LAM vs HBIG + ETV or TDF, although a recent systematic review noted a higher recurrence rate with the combination HBIG + LAM than with HBIG + ETV/TDF (6.1% vs 1%, P = 0.0004) [27] .…”

Section: Combined Prophylaxis With Hbig Plus Oral Antiviralsmentioning

confidence: 99%

Management of hepatitis B virus infection after liver transplantation

Jiménez‐Pérez

González‐Grande

Torres

et al. 2015

WJG

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is responsible for up to 30% of cases of liver cirrhosis and up to 53% of cases of hepatocellular carcinoma. Liver transplantation (LT) is the best therapeutic option for patients with end-stage liver failure caused by HBV. The success of transplantation, though, depends on receiving prophylactic treatment against post-transplant viral reactivation. In the absence of prophylaxis, liver transplantation due to chronic hepatitis B (CHB) is associated with high rates of viral recurrence and poor survival. The introduction of treatment with hepatitis B immunoglobulins (HBIG) during the 1990s and later the incorporation of oral antiviral drugs have improved the prognosis of these patients. Thus, LT for CHB is now a universally accepted option, with an estimated 5 years survival of around 85% vs the 45% survival seen prior to the introduction of HBIG. The combination of lamivudine plus HBIG has for many years been the most widely used prophylactic regimen. However, with the appearance of new more potent oral antiviral agents associated with less resistance (e.g., entecavir and tenofovir) for the treatment of CHB, new prophylactic strategies are being designed, either in combination with HBIG or alone as a monotherapy. These advances have allowed for more personalized prophylaxis based on the individual risk profile of a given patient. In addition, the small pool of donors has required the use of anti-HBc-positive donors (with the resulting possibility of transmitting HBV from these organs), which has been made possible by suitable prophylactic regimens.

show abstract

Clinical Outcomes and Risk Factors of Hepatitis B Virus Recurrence in Patients Who Received Prophylaxis With Entecavir and Hepatitis B Immunoglobulin Following Liver Transplantation

Cited by 16 publications

References 17 publications

The Strategy and Efficacy of Prophylaxis Against Hepatitis B Virus Recurrence After Liver Transplantation in the Era of High Potent Nucleos(t)ide Analogues: A Meta-Analysis

The Strategy and Efficacy of Prophylaxis Against Hepatitis B Virus Recurrence After Liver Transplantation in the Era of High Potent Nucleos(t)ide Analogues: A Meta-Analysis

Hepatitis B immune globulin and HBV-related liver transplantation

Management of hepatitis B virus infection after liver transplantation

Contact Info

Product

Resources

About